WCG Releases 2024 Report on Top Issues Impacting Clinical Research Sites
PRINCETON, N.J., Oct. 8, 2024 /PRNewswire/ -- WCG, the global leader in providing solutions that measurably improve the quality and...
Clinical Trial
UFC’s Michael Chandler Joins “Official UFC Partner” Aires Tech To Champion EMF Protection As Brand Partner
Chandler strengthens the #AiresAthletes campaign, reinforcing the importance of EMF protection to enhance recovery and overall well-being*Chandler fuels Aires' brand...
Florence Healthcare Partners with ScienceMedia to Ease Training Burden for Clinical Sites
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- ScienceMedia, a global SaaS clinical trial training solution provider, and Florence Healthcare, the...
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT /...
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
TORONTO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a...
Parexel’s Teri Karcher Named to 2024 PharmaVoice 100
Chief Drug Development Officer and Executive Vice President, Head of Launch Excellence recognized for pioneering leadership in drug development DURHAM,...
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities
DENVER , Oct. 08, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing...
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to...
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet...
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
SANTA ANA, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage...
ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301
Safety, pharmacokinetics and target engagement data from first-in-human Phase 1 clinical trial in healthy volunteers will potentially enable rapid advancement...
Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
DURHAM, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable,...
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage...
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief...
SIGA Announces Agreement to Supply TPOXX® in Morocco
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader...
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of...
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board...
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase...
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen...
COSCIENS Biopharma Announces Change to Board of Directors
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a...